References
- Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
- Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2017 May 9;7:72.
- Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexateas second-line treatment in patients with recurrent or metastaticsquamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label,randomised phase 3 trial. Lancet Oncol. 2015;16(5):583–594.
- Ferris RL, Licitra L, Fayette J, et al. Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): efficacy and safety in CheckMate 141 by prior cetuximab use. J Clin Oncol. 2017;35(suppl):6020(abstract).
- Addeo R, Caraglia M, Iuliano G. Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opin Biol Ther. 2016;16(9):1075–1078.
- Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2018;S0140-6736(18)31999–8. [Epub ahead of print]. DOI:10.1016/S0140-6736(18)31999-8.
- Scarpati GD, Perri F, Ricciardiello F, et al. The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy. Oral Oncol. 2014;50:e1–e2.
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127.
- [cited 2018 Apr 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf
- [cited 2018 Apr 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf
- Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eear3593.